Drug Profile
Plevitrexed
Alternative Names: BGC 9331; ZD 9331Latest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator AstraZeneca; BTG; Cancer Research UK Centre for Cancer Therapeutics
- Developer BTG
- Class Antineoplastics; Tetrazoles
- Mechanism of Action Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Gastric cancer; Ovarian cancer; Pancreatic cancer
- Discontinued Colorectal cancer; Solid tumours
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 06 Dec 2010 No development reported - Phase-I/II for Gastric cancer in Europe (IV-infusion)
- 06 Dec 2010 No development reported - Phase-II for Gastric cancer in Czech Republic (IV-infusion)